Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2 , with IC 50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.
Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ERK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.